- Home
- ADCT vs NPCT Comparison
ADCT vs NPCT Comparison
Compare ADCT & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- NPCT
- Stock Information
- Founded
- ADCT 2011
- NPCT 2020
- Country
- ADCT Switzerland
- NPCT United States
- Employees
- ADCT N/A
- NPCT N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- NPCT Investment Managers
- Sector
- ADCT Health Care
- NPCT Finance
- Exchange
- ADCT Nasdaq
- NPCT Nasdaq
- Market Cap
- ADCT 241.0M
- NPCT 284.1M
- IPO Year
- ADCT 2020
- NPCT N/A
- Fundamental
- Price
- ADCT $2.97
- NPCT $10.77
- Analyst Decision
- ADCT Strong Buy
- NPCT
- Analyst Count
- ADCT 5
- NPCT 0
- Target Price
- ADCT $7.75
- NPCT N/A
- AVG Volume (30 Days)
- ADCT 694.8K
- NPCT 107.1K
- Earning Date
- ADCT 05-14-2025
- NPCT 01-01-0001
- Dividend Yield
- ADCT N/A
- NPCT 9.82%
- EPS Growth
- ADCT N/A
- NPCT N/A
- EPS
- ADCT N/A
- NPCT N/A
- Revenue
- ADCT $75,817,000.00
- NPCT N/A
- Revenue This Year
- ADCT $9.19
- NPCT N/A
- Revenue Next Year
- ADCT $16.27
- NPCT N/A
- P/E Ratio
- ADCT N/A
- NPCT N/A
- Revenue Growth
- ADCT 10.49
- NPCT N/A
- 52 Week Low
- ADCT $1.05
- NPCT $8.58
- 52 Week High
- ADCT $4.13
- NPCT $10.63
- Technical
- Relative Strength Index (RSI)
- ADCT 75.65
- NPCT 69.97
- Support Level
- ADCT $1.83
- NPCT $10.04
- Resistance Level
- ADCT $2.35
- NPCT $10.27
- Average True Range (ATR)
- ADCT 0.31
- NPCT 0.12
- MACD
- ADCT 0.12
- NPCT 0.06
- Stochastic Oscillator
- ADCT 93.03
- NPCT 95.14
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.